A second-generation blood substitute (perfluorodichlorooctane emulsion) does not activate complement during an ex vivo circulation model of bypass.
OBJECTIVE
To examine whether a second-generation perfluorocarbon (PFC) blood substitute added to the cardiopulmonary bypass (CPB) prime influences complement production.


METHODS
A prospective, randomized, single-blinded, ex vivo model.


METHODS
A university hospital, laboratory, and clinics.


METHODS
Ten healthy adult consented volunteer blood donors (five men, five women).


METHODS
Ex vivo closed-loop extracorporeal circuit including membrane oxygenator, tubing, and filter primed with crystalloid or crystalloid plus PFC was circulated for 1 hour with the addition of 500 mL of heparinized fresh human whole blood.


RESULTS
Laboratory specimens were drawn from the circuit at 10-minute intervals for 1 hour and measured for complement (C3a, Bb fragment) concentrations, blood gases, fibrinogen concentration, platelet count, and hematocrit. In the PFC group, C3a and Bb fragments were equal to or less than those in the group that received crystalloid alone.


CONCLUSIONS
The second-generation PFC added to the prime of a CPB circuit does not independently increase complement production.
Department of Anesthesiology, University of Washington, Seattle 98195, USA.
J D
JD
Rosoff
L O
LO
Soltow
C R
CR
Vocelka
G
G
Schmer
W L
WL
Chandler
R P
RP
Cochran
K S
KS
Kunzelman
B D
BD
Spiess
D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001802:Blood Substitutes / Q000008:administration & dosage / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass / Q000295:instrumentation / Q000379:methods; D003167:Complement Activation / Q000187:drug effects*; D015926:Complement C3a / Q000032:analysis / Q000096:biosynthesis; D011415:Complement Factor B / Q000032:analysis / Q000096:biosynthesis; D000077324:Crystalloid Solutions; D004655:Emulsions; D005260:Female; D005374:Filtration / Q000295:instrumentation; D005466:Fluorocarbons / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006843:Hydrocarbons, Chlorinated / Q000008:administration & dosage / Q000627:therapeutic use*; D006845:Hydrocarbons, Fluorinated / Q000008:administration & dosage / Q000627:therapeutic use*; D007552:Isotonic Solutions; D008297:Male; D008875:Middle Aged; D010107:Oxygenators, Membrane; D010952:Plasma Substitutes / Q000627:therapeutic use; D011446:Prospective Studies; D016037:Single-Blind Method
D000925:Anticoagulants; D001802:Blood Substitutes; D000077324:Crystalloid Solutions; D004655:Emulsions; D005466:Fluorocarbons; D006843:Hydrocarbons, Chlorinated; D006845:Hydrocarbons, Fluorinated; D007552:Isotonic Solutions; D010952:Plasma Substitutes; C114895:perfluorodichlorooctane; D015926:Complement C3a; D006493:Heparin; D011415:Complement Factor B